anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition for oxidatively dyeing a keratinous fiber such as a human hair by including an oxidizing base, an ammonia generating two-electron oxidoreductase type enzyme and a donor for the above enzyme in a medium suitable for dyeing. SOLUTION: This composition is obtained by including (A) at least one oxidizing base (e.g. p-phenylenediamines, double bases, p-aminophenols, o-aminophenols or heterocyclic oxidizing bases), (B) at least one ammonia generating two- electron oxidoreductase type enzyme (e.g. D-aspartate oxidase) and (C) at least one donor for the above enzyme (e.g. D-aspartic acid or D-glutamic acid is cited as the donor for the D-aspartate oxidase). The respective preferred contents of the ingredients A to C are 0.0005-12 wt.% of the ingredient A, 0.01-40 wt.% of the ingredient B and 0.01-20 wt.% of the ingredient C.
During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
The invention relates to a bleeding stopping and blood platelet increasing honeyed bolus. The bleeding stopping and blood platelet increasing honeyed bolus is prepared from 15-19g of patience dock roots, 9-11g of red coatings, 5-7g of human placenta and 5-7g of codonopsis pilosula. The bleeding stopping and blood platelet increasing honeyed bolus is prepared by the following steps: firstly, respectively crushing medicines in the formula for the first time; finely crushing for the second time after coarse screening; then, finely screening to remove impurities, and mixing the obtained powder; adding a proper amount of honey, and mixing to prepare the honeyed bolus. Two honeyed boluses for increasing blood platelet are orally taken every time, three times per day by the patient, and one week is a treatment course and after two treatment courses, the honeyed boluses become effective. 40 volunteers are extracted from hospitalized patients with hemorrhage syndrome or thrombocytopenia for test. After blood routine examination, liver function and renal function of the testees, except laxativeness for individuals, the bleeding stopping symptoms of others are improved, the blood platelets are increased by 90.1% and no remarkable toxic or side effects are found. Therefore, the bleeding stopping and blood platelet increasing honeyed bolus provided by the invention has a remarkable effect on patients with primary thrombocytopenia and has a good bleeding stopping effect on various hemorrhage syndromes.
160 St. Jude families with a cancer patient who meets eligibility criteria will be enrolled on the study. Eligible St. Jude patients must be 17 years of age or younger at the time of enrollment. They must also be at least one month from initial diagnosis and in active treatment. The patient cannot currently be using tobacco, and he/she must live with at least one cigarette smoking adult who smokes in his/her presence. Both smoking and non-smoking parents are eligible to participate. The inclusion of non-smoking parents reflects the primary objective of the proposed study to reduce ETS exposure in the child's environment. We will evaluate the efficacy of an ETS intervention by using a randomized controlled trial design that incorporates an experimental intervention group (ETS) and a standard care control group (SCC). Parents in the SCC group will receive the standard advice with no additional intervention. The experimental group will participate in a three month, multi-component behavioral program focused on the reduction of the cancer patient's ETS exposure. The program will consist of three bi-weekly face-to-face coaching sessions followed by three bi-weekly telephone coaching sessions that will occur within the first three months following enrollment onto the study. Although telephone counseling sessions will be offered for parents who are not available in person, the face-to-face sessions are encouraged as much as possible. Parents in this group will receive physician feedback letters acknowledging their participation and progress at the start and end of the coaching phase, as well as, a follow-up telephone contact at five months. Self-report and biological measures will be obtained from all families during clinic visits at baseline and at three, six, nine, and twelve months. Reported ETS exposure and the child's urine cotinine levels will serve as the primary dependent variables. Other psychosocial and health outcomes will also be assessed. Children 10 years of age and older will complete a brief ETS exposure questionnaire that asks them to report on exposure in their environment. Parents in each group will be paid $10 for each set of study forms they answer. The total amount that a parent in the control group may receive is $50. Parents in the ETS intervention program will also receive $12.50 for each face-to-face and telephone coaching session in which they take part. The telephone follow-up call occurring at five months will not be compensated. The total amount that a parent in the ETS intervention group may receive is $125. Patients will receive a $10 hospital gift voucher for each urine sample they provide. The total amount that a patient may receive is $50 to $60. At the end of the study, parents who were assigned to the standard advice control group may receive the ETS intervention program without charge, if they so choose. Also, parents in both groups may choose to receive feedback about their child's urine cotinine results at the completion of the study.
Transcutaneous Electrical Spinal Stimulation (TESS) is applied for 20 minutes prior to BCI training sessions. Following TESS, BCI training is performed with visual feedback contingent to motor imagery as detected by a closed-loop BCI.
Transfection particles for delivery of nucleic acid into higher eucaryotic cells in vitro and in vivo comprises one or more nucleic acid molecules condensed by organic cationic molecules. The discrete and stable particles are obtained by complexing the nucleic acid molecules with identical or different organic cationic precursor molecules without crosslinking nucleic acid molecules, and covalently linking the precursor molecules to each other on the nucleic acid template. For specific cellular targeting, the particles may carry targeting molecules, e.g. sugars. Preferred cationic precursor molecules are lipophilic detergents that are linked to form lipids. The particles contain preferably only one nucleic acid molecule which makes them useful for gene therapy and for delivery of large DNA molecules. <IMAGE>
BACKGROUND: To evaluate the treatment outcomes of lateral interbody bone graft surgery and posterior percutaneous screws for lumbar spinal stenosis Methods: This is a cross-sectional descriptive study. There were 27 patients with 30 segments of surgery diagnosed with lumbar spinal stenosis that were surgically treated with the XLIF method. Clinical outcomes measured included VAS scores for lower back pain and leg pain, ODI, and JOA scores. Magnetic resonance imaging of the lumbar spine after surgery was used to evaluate indirect decompression. X-ray or CT scan to evaluate bone fusion after 6 months of surgery. Differences were determined by independent T-test.
RESULTS: There were 27 patients with 30 segments of surgery. They were 12 males and 15 females with an average age of 58.81±8.1. There was significant improvement in VAS for lower back pain from 7.11±1.31 to 3.67±1.3, VAS for leg pain from 6.81±2.19 to 1.59±1.89, ODI from 26.41±8.95 to 13.69±8.34, and JOA score from 7.63±2.87 to 13.5±1.73. A-P diameter increased 134%, lateral diameter increased 120%, lateral recess depth increased 166%, disc height increased 126%, foraminal height increased 124%, spinal canal area increased 30%. The p-values were all <0.001. The average hospital stay was 6.79±3.01 days. Complications included 1 pedicle screw malformation, 1 ALL avulsion fracture, 1 abdominal herniation, 1 venous damage, 1 failure.
CONCLUSION: XLIF surgery presents a favorable option for patients with lumbar spinal stenosis. This is a minimally invasive surgical method that reduces pain, reduces bleeding, and is effective in indirectly decompressing the spinal canal both clinal and imaging.
Constraint-Induced Movement therapy or CI therapy is a rehabilitation method, based on behavioral neuroscience studies of deafferented monkeys, that has been shown in controlled studies to produce large improvements in real-world upper-extremity use in individuals with chronic stroke. Up till now, survivors of stroke with plegic hands have been excluded from CI therapy protocols, whether on a research or clinical basis. Such individuals are estimated to make up at least 35% of the population with chronic stroke with residual motor deficit. Furthermore, there are no other interventions for such individuals that have controlled evidence of efficacy for increasing real-world function. Thus, these stroke survivors represent a large number of healthcare consumers with limited treatment options.

We recently completed a pilot study of a modified form of CI therapy for stroke survivors with plegic hands, and obtained surprisingly positive findings. Six individuals were enrolled who had a flicker of active movement at the elbow and at the wrist or a finger and 30° of active range of motion at the shoulder. Participants received three weeks of CI therapy, combined with other modes of therapy, for six hours per day. The treatment package included tone management/movement facilitation, training of more-impaired arm use using shaping, functional task practice, restraint of the less-impaired arm in the laboratory and at home as indicated, and a package of behavioral methods for transferring gains from the laboratory to the home situation. As a group, the patients showed a large improvement in more-impaired arm use in daily life after treatment (Motor Activity Log or MAL; p's \< 05, Effect Size \> 1.5). Improvements in more-impaired arm motor ability, as measured by scores on a laboratory motor performance test (graded Wolf Motor Function Test; gWMFT) and standardized clinical examination (Fugl-Meyer), were also substantial (p's \< .05).

Based on these initial findings, we propose a randomized, controlled clinical trial to rigorously test the efficacy of this modification of CI therapy for rehabilitating arm function in chronic stroke patients with severe upper-extremity impairment. To this end, 40 survivors of stroke with plegic hands will be randomly assigned to receive the intervention described above or a placebo control procedure of the same duration. Control participants will receive either 1) tone management, EMG biofeedback and other procedures in alternating blocks for 6 hr daily for 15 consecutive weekdays or 2) usual \& customary care. Measures of arm motor ability (gWMFT; Fugl-Meyer), arm use in daily life (MAL, accelerometry), and quality of life (Stroke Impact Scale) will be administered to all participants before and after treatment and at long-term. If the modified CI therapy participants shows larger improvements in more-impaired arm function than the control group participants, this will suggest it is an efficacious treatment and raise hopes of additional recovery for a large group of healthcare consumers with limited treatment options.
PURPOSE:To make invitro decision of eye stimulativeness with good reproducibility by including a marker to be brought into contact with the material to be inspected in liposome to prepare a reagent for deciding the eye stimulus. CONSTITUTION:The liposome constitutes the bilayer endoplasmic reticulum of the lamela layer prepd. from specific lipid and is prepd. of 1): >=1 kinds selected from natural phospholipid, synthetic phospholipid, natural glycolipid and mixture composed of quaternary ammonium salt and higher alcohol and 2): >=1 kinds selected from neutral lipids. For example, lecithin which is the lipid of 1) and cholesterol or the like which is the lipid of 2) are used. The marker is used to detect a change in the film properties of the liposome by interaction with a material to be inspected. A compd. contg. K<+> ion, F<-> ion, etc., is used for said marker. The reagent is prepd. by including the marker into the liposome. The eye stimulativeness is evaluated by bringing this reagent into contact with the material to be inspected and detecting that the liposome film is broken and the marker is leaked. The simple determination of the eye stimulativeness is thus permitted.
The invention discloses a Chinese herbal medicine mixture for treating abdominal pain and diarrhea. The mixture is characterized by comprising two raw materials cortex phellodendri Chinensis and cynanchum paniculatum (Bge.) Kitag., wherein the mass ratio of two raw materials is (2-10): (1-9). As an improvement, the Chinese herbal medicine mixture comprises cortex phellodendri Chinensis extract and cynanchum paniculatum (Bge.) Kitag. extract and the mass ratio of the cortex phellodendri Chinensis extract to the cynanchum paniculatum (Bge.) Kitag. extract is that of the two raw materials, namely the mass ratio of the cortex phellodendri Chinensis extract to the cynanchum paniculatum (Bge.) Kitag. extract is (2-10):(1-9). The mixture uses the two Chinese medicinal herbs of cynanchum paniculatum (Bge.) Kitag. and cortex phellodendri Chinensis and extracts thereof with an enhanced efficacy and anti-inflammatory, anti-allergic, analgesic and antidiarrheal effects; and simultaneously, the mixture has the anti-inflammatory, analgesic, antidiarrheal and anti-allergic effects, and is good in curative effect, convenient to use and multi-effect.
The invention provides a compound essential oil for improving sleep, calming and relieving depression and a composition thereof. The compound essential oil comprises the following raw materials in parts by weight: 5-40 parts of perilla essential oil, 1-10 parts of magnolia officinalis essential oil, 5-20 parts of orange shell essential oil, 5-20 parts of angelica essential oil, 0.1-5 parts of safflower essential oil, 1-10 parts of costus essential oil, 1-10 parts of red peony root essential oil, 5-30 parts of sappan wood essential oil, 0.01-2 parts of nutgrass galingale rhizome essential oil, 0.05-2 parts of gardenia kernel essential oil and 0.05-2 parts of spina date seed essential oil. The composition comprises any one of coated essential oil, sachet, medicated pillow, medicated incense, navel patch and sachet. The sachet or sachet comprises 10 parts of agilawood, 5 parts of basil, 15 parts of frankincense, 20 parts of rose, 30 parts of lavender and 20 parts of the compound essential oil. The coating essential oil comprises 40-80 parts of the compound essential oil, 20-60 parts of gardenia kernel oil and 20-60 parts of spine date seed oil. The composition and the coating essential oil provided by the invention can effectively improve sleep functional diseases caused by various factors and have the effect of relieving depression.
Oral ingestion of nitrate (NO3-) in the form of both nitrate salts and beetroot juice has been shown to significantly lower blood pressure at rest and to also lower pulmonary oxygen uptake during exercise, in addition to improving exercise performance during cycle time trial. However, there has been no consensus on the optimal supplementation protocols, in terms of duration of supplementation to see these metabolic effects. Furthermore, a positive exercise performance effect of nitrate ingestion has primarily been observed in recreational athletes. The potentially ergogenic effects of nitrate in well-trained or elite athletes therefore remain to be fully established. Based on the gaps in current literature, our main goal will be to gain further insight into different aspects of nitrate supplementation to enhance (elite) sports performance. This will be investigated in this study by assessing the effect of an acute vs. chronic supplementation period of sodium nitrate (NaNO3-) on exercise performance.
An existing denture is lined with silicone rubber by a process comprising relining the denture with new acrylic material, applying a room temperature vulcanisable silicone rubber to the new acrylic material and vulvanising the silicone rubber.  In one embodiment the process comprises the steps of (1) taking an already existing denture (which is deficient in its gum contacting area) and applying an impression material to the gum-contacting surface thereof (2) taking a reline impression (i.e. new impression of the gum surface) (3) making a stone model of the gum contacting side of the denture by using the denture with the reline in it (4) making a counterpart of the stone model (i.e. a model of the reverse side of the denture to the gum contacting side) by pouring the mould forming material on said reverse side, (5) trimming the top surface of the counterpart and the bottom surface of the model so that they are both level, (6) removing the denture with the impression material (reline) and removing the impression material from the denture, (7) hollowing out the original gum contacting surface of the original denture, (8) applying new acrylic material to the hollowed out portion and allowing this to set, (9) priming the surface of the applied acrylic material and allowing the primer to dry, (10) seating the denture in the counterpart, (11) applying a room-temperature vulcanisable silicone rubber to the primed surface, (12) seating the silicone rubber coated surface on the model and applying pressure to press the counterpart and the model together, (13) fracturing the model when the silicone rubber is cured and recovering the relined denture. Alternatively the procedure can be carried out in a dental flask. The acrylic material is preferably methyl methacrylate and silicone rubbers having a p  basis of polydimethylsiloxane polymer with a minor proportion of silica filler and pigment paste may be used.
Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if \> 1 year. 50ug daily for 4 days if \< 1 year.
The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
VELCADE is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied. 

Monitor complete blood counts (CBC) frequently during treatment with VELCADE. Measure platelet counts prior to each dose of VELCADE. Adjust dose/schedule for thrombocytopenia [see  Dosage and Administration (2.6)]. Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with VELCADE. Support with transfusions and supportive care, according to published guidelines. 

In the single agent, relapsed multiple myeloma study of VELCADE vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 8. The incidence of bleeding (≥Grade 3) was 2% on the VELCADE arm and was <1% in the dexamethasone arm. 

In the combination study of VELCADE with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12. The incidence of bleeding events (≥Grade 3) was 1.7% in the VcR-CAP arm (four patients) and was 1.2% in the R-CHOP arm (three patients). 

Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm. 

The incidence of neutropenia (≥Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm. The incidence of febrile neutropenia (≥Grade 4) was 5% in the VcR-CAP arm and was 6% in the R-CHOP arm. Myeloid growth factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm.
The study was designed to determine the capacity of self-efficacy to predict maintenance of the practices of PFMT and BT. Women in the treatment arm of the RCT attended a Bladder Health Class (PFMT \& BT) to prevent UI. The class content emphasized self-efficacy. At 3-months post intervention the self-efficacy of participants was measured; these results were collected to analyze for predictive capacity of training adherence. For four years participants in both the treatment and control (no class) arms were followed with both questionnaires and 3-day bladder diaries (2/year) and clinic evaluations of (1/year). In addition, qualitative analyses of the narratives of Bladder Health Class participants identified individual attitudes and strategies that either facilitated or deterred adherence.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of specifically inhibiting the synthesis of a heat-shock protein having 16-40k dalton molecular weight and effectively retreating a cancer, multiple sclerosis, etc., by including atractylenolide III or its stereoisomer as an active ingredient. SOLUTION: This medicine includes atractylenolide III [i.e., 54a,5,6,7,8,8a,9,9a- octahydro-9a-hydroxy-3,8a-dimethyl-5-methylene-naphtho(2,3-b)furan-2(4 H)-one] or its stereoisomer as an active ingredient. The atractylenolid is obtained, e.g. by extracting Atractylodis rhizome which is a crude medicine. The objective medicine preferably includes the above active ingredient in an amount of 0.1-80wt.%. The medicine is administered in a daily does of 1mg-10g for an adult in one to four divided portions. Moreover, as the above-mentioned heat- shock proteins HSP 27 of a mammal is cited.
This was a prospective, interventional trial. The investigators enrolled a cohort of consenting, healthy physicians, nurses, and ancillary staff at a teaching facility who did not have known hypersensitivity to foam tape. Study investigators applied a 2x2 inch piece of 3M micro-foam adhesive to the medial aspect of each subject's upper arm. The contralateral arm served as a reference for comparison. The adhesive remained in place for 48 hours and the study authors assessed patients utilizing the previously validated Cutaneous Irritancy Scoring System (CISS). Categorical variables analyzed by chi-square, continuous variables with t-tests.